Opus Genetics' eye drop shows promise for age-related vision loss in Phase 3 trial. Company plans FDA filing to expand medication's approved uses.

Check out our SOPH stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today. SOPH - Sophia Genetics SA Chart ...

Retinal dystrophies are a heterogeneous group of diseases in which the retina degenerates, leading to either partial or complete blindness. The severe and clearly hereditary forms, retinitis ...

The trial showed 27.2% of patients treated with the eye drop achieved a significant improvement in near vision without compromising distance vision, compared to 11.5% on placebo. This improvement was ...

Crayola aims to foster a worldwide community of color‑makers who believe in the power of art to connect, heal, and inspire. To support this mission, Crayola is offering a suite of easy‑to‑use creative ...